<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157040</url>
  </required_header>
  <id_info>
    <org_study_id>060101</org_study_id>
    <nct_id>NCT00157040</nct_id>
  </id_info>
  <brief_title>Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A</brief_title>
  <official_title>Recombinant Antihemophilic Factor (rAHF-PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Pharmacokinetics, Immunogenicity, Efficacy and Safety in Previously Treated Pediatric Patients With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the&#xD;
      treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study&#xD;
      is a pharmacokinetic evaluation, and Part 2 is an evaluation of efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2002</start_date>
  <completion_date type="Actual">January 4, 2005</completion_date>
  <primary_completion_date type="Actual">January 4, 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The terminal phase half-life of Recombinant Antihemophilic Factor (rAHF-PFM)</measure>
    <time_frame>Within 30 minutes prior to the pharmacokinetic infusion and at 1 hour ± 5 minutes, 9 ± 1 hour, 24 ± 2 hours, and 48 ± 2 hours after the infusion</time_frame>
    <description>Terminal phase half-life of rAHF-PFM was to be determined using the biphasic linear regression model.</description>
  </primary_outcome>
  <enrollment>50</enrollment>
  <condition>Hemophilia A</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihemophilic factor, recombinant, manufactured protein-free</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is less than 6 years of age&#xD;
&#xD;
          -  Severe or moderately-severe hemophilia A as defined by a baseline factor VIII level &lt;=&#xD;
             2%, documented at screening or on the basis of historical data (e.g., at hemophilia&#xD;
             diagnosis)&#xD;
&#xD;
          -  Documented medical history of at least 50 exposure days for treatment with all other&#xD;
             factor VIII products&#xD;
&#xD;
          -  Subject's parent or legally authorized representative has provided informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Detectable inhibitor to factor VIII measured in the screening sample by the local or&#xD;
             central hemostasis laboratory&#xD;
&#xD;
          -  History of inhibitor to factor VIII at any time prior to screening&#xD;
&#xD;
          -  Subject has any one of the following laboratory abnormalities at the time of&#xD;
             screening:&#xD;
&#xD;
               1. platelet count &lt; 100,000/mm3&#xD;
&#xD;
               2. hemoglobin concentration &lt; 10 g/dL (100 g/L)&#xD;
&#xD;
               3. serum creatinine &gt; 1.5 times the ULN for age&#xD;
&#xD;
               4. total bilirubin &gt; 2 times the ULN for age&#xD;
&#xD;
          -  Subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g.,&#xD;
             platelet dysfunction secondary to uremia, liver failure, von Willebrand's Disease)&#xD;
&#xD;
          -  Subject has known hypersensitivity to RECOMBINATE rAHF&#xD;
&#xD;
          -  Subject is currently participating in another investigational drug study or has&#xD;
             participated in any clinical study involving an investigational drug within 30 days of&#xD;
             study entry&#xD;
&#xD;
          -  Subject is identified by the investigator as being unable or unwilling to cooperate&#xD;
             with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children´s Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Department of Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children´s Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Bleeding Disorders Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hemophilia Treatment Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children´s Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children´s Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children, Division of Hematology/Oncology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Pediatric Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor VIII Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

